^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Ruxience (rituximab-pvvr) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Therapeutic Goods Administration
    Published date:
    03/10/2021
    Excerpt:
    Australian prescription medicine decision summary...Ruxience (rituximab) was approved for the following therapeutic use...Non-Hodgkin's lymphoma...CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma, in combination with chemotherapy
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/26/2020
    Excerpt:
    RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with...Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
    Secondary therapy:
    CHOP; Chemotherapy
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    04/01/2020
    Excerpt:
    Ruxience is indicated for the treatment of patients with CD20 positive diffuse large B cell non‑Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
    Secondary therapy:
    CHOP